PRR11 and neoplasm: The intensity of the PRR11 staining had significant differences between benign lesions and stage I/II and between stage III/IV and intravascular tumor emboli of IHC as follows: 0.115 ± 0.29 in benign lesions, 0.32 ± 0.39 in intraepithelial neoplasm (IEN) lesions, 0.51 ± 0.60 in tumors at stage I/II, 0.62 ± 0.63 in tumors at stages III/IV, and 3–0.29 in intravascular tumor emboli (Fig. 1c-d).